8-K: Foghorn Therapeutics Advances Pipeline, Cuts Q2 Loss

Foghorn Therapeutics reported reduced net losses and strong cash reserves, alongside significant progress in its oncology pipeline, including its lead candidate FHD-909 and multiple selective degrader programs.

Summary

• Foghorn Therapeutics reported a net loss of $17.9 million for the three months ended June 30, 2025, a decrease from $23.0 million for the same period in 2024.
• Collaboration revenue increased to $7.6 million for Q2 2025, up from $6.9 million in Q2 2024, driven by the Lilly Collaboration Agreement.
• Research and development expenses decreased to $21.8 million in Q2 2025 from $23.8 million in Q2 2024, primarily due to lower FHD-286 costs and personnel-related expenses.
• General and administrative expenses also decreased to $6.9 million in Q2 2025 from $7.3 million in Q2 2024.
• The company held $198.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing a cash runway into 2028.
• The FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with NSCLC as the primary target, is enrolling well and remains on track.
• Preclinical data showed synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors in NSCLC animal models.
• The Selective CBP degrader program is on track for IND-enabling studies, targeting an IND in 2026, with encouraging activity in ER+ breast cancer.
• Program updates are expected in Q4 2025 for both the Selective EP300 degrader, which showed robust anti-tumor activity in hematologic malignancies, and the Selective ARID1B degrader, which achieved selective targeted degradation.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, driven by reduced net loss, increased collaboration revenue, and significant progress across its clinical and preclinical pipeline. The extended cash runway into 2028 provides substantial financial stability, and promising preclinical data for combination therapies enhance future potential. While still operating at a loss, the trajectory and pipeline advancements are highly favorable for a clinical-stage biotechnology company.

Positives

• Net loss significantly decreased to $17.9 million in Q2 2025 from $23.0 million in Q2 2024.
• Collaboration revenue increased, indicating continued advancement of programs under the Lilly Collaboration Agreement.
• Research and development expenses and general and administrative expenses both decreased, reflecting improved cost management.
• The FHD-909 Phase 1 dose escalation trial is enrolling well and remains on track, with the first patient dosed in October 2024.
• Preclinical data for FHD-909 demonstrated synergistic anti-tumor activity when combined with pembrolizumab and KRAS inhibitors, supporting broader clinical exploration.
• The Selective CBP degrader program is advancing towards an IND in 2026, showing encouraging activity in ER+ breast cancer.
• Significant progress was made on Selective EP300 and ARID1B degrader programs, with updates expected in Q4 2025, demonstrating successful selective degradation and anti-tumor activity.
• A strong balance sheet with $198.7 million in cash, cash equivalents, and marketable securities provides a cash runway into 2028.

Negatives

• The company continues to report a net loss, albeit reduced, indicating ongoing operational expenses exceeding revenue.
• Cash, cash equivalents, and marketable securities decreased to $198.7 million as of June 30, 2025, from $243.7 million as of December 31, 2024, reflecting cash burn.
• Total stockholders deficit increased to $(76.659) million as of June 30, 2025, from $(45.528) million as of December 31, 2024.

Risks

• Actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.
• Risks relate to clinical trials, including their initiation, timing, progress, and results.
• The ability to advance product candidates and successfully complete preclinical and clinical studies is subject to risk.
• Exogenous factors, including macroeconomic and geopolitical circumstances, may impact business operations and research and development programs.
• Developments related to competitors and the industry could affect the company's position.
• The ability to expand target populations and the availability of patients for clinical testing are uncertain.
• Obtaining regulatory approval for FHD-909 and future product candidates from the FDA and other regulatory authorities is not guaranteed.
• The ability to identify and enter into future license agreements and collaborations is a risk.
• Reliance on CDMOs and CROs for manufacturing and research needs carries inherent risks.
• Regulatory developments in the United States and foreign countries could impact operations.
• The ability to attract and retain key scientific and management personnel is crucial and subject to risk.
• Establishing, maintaining, and enforcing intellectual property rights covering products and the Gene Traffic Control Platform is a challenge.
• Estimates of expenses, capital requirements, and needs for additional financing are subject to change.

Future Outlook

The company expects continued progress in its pipeline, with the FHD-909 Phase 1 trial remaining on track and potential for clinical exploration of FHD-909 in combination with other therapies. It targets an Investigational New Drug (IND) application for its Selective CBP degrader in 2026 and anticipates program updates for its Selective EP300 and ARID1B degraders in Q4 2025. The company projects its current cash, cash equivalents, and marketable securities will provide a runway into 2028, supporting further advancement of its differentiated programs.

Management Comments

• "We continue to make meaningful progress advancing our pipeline to treat a wide range of cancers."
• "The FHD-909 dose escalation trial, which is part of our strategic collaboration with Lilly, is enrolling well and remains on track."
• "Additionally, preclinical synergistic activity of FHD-909 in combination with KRAS inhibitors and pembrolizumab supports clinical exploration of FHD-909 in difficult-to-treat NSCLC."
• "Our wholly owned selective degrader programs targeting CBP, EP300 and ARID1B, continue to advance with strong momentum."
• "Our Selective CBP degrader has shown encouraging activity in ER+ breast cancer with potential beyond EP300-mutant tumors, and we are targeting an IND in 2026."
• "Additionally, we anticipate program updates in the fourth quarter of 2025 for both our Selective EP300 degrader, which has shown robust anti-tumor activity across a range of hematologic malignancies, and our Selective ARID1B degrader, which has achieved selective targeted degradation."
• "Backed by a strong balance sheet and a cash runway into 2028, we are well positioned to further advance our differentiated programs."

Industry Context

This announcement highlights Foghorn Therapeutics' position as a leader in chromatin biology, a unique area of cancer research implicated in up to 50% of all tumors. The company's focus on precision therapeutics, particularly selective protein degraders and inhibitors, addresses previously 'undruggable' targets like SMARCA2, CBP, EP300, and ARID1B. This aligns with the broader industry trend towards targeted therapies and synthetic lethality approaches, exemplified by the success of PARP inhibitors, aiming to induce tumor death while sparing healthy cells. The strategic collaboration with Lilly underscores the industry's interest in innovative platforms for oncology drug discovery and development.

Comparison to Industry Standards

• FHD-909 is described as the 'first selective SMARCA2 inhibitor in the clinic,' addressing a challenge where the industry has previously failed to develop a selective inhibitor for SMARCA2.
• The company's Selective CBP and EP300 degraders aim to overcome the toxicity issues associated with dual inhibition of CBP/EP300, a common challenge in the field, by achieving high selectivity (e.g., FHT-CBPd-59 with >1000x selectivity for CBP over EP300, and FHT-EP300d-53 with >1000x selectivity for EP300 over CBP).
• Preclinical data for the Selective EP300 degrader demonstrated complete tumor regression in multiple myeloma models, a deeper response compared to non-selective dual CBP/EP300 inhibitors like CCS1477 (Inobrodib), which showed only tumor stasis and clinical safety issues (thrombocytopenia).
• Foghorn is the 'first to report selective degradation of ARID1B,' a target previously considered undruggable due to its lack of enzymatic activity and high similarity to ARID1A.
• The company's approach of exploiting synthetic lethality (e.g., SMARCA2 inhibition in SMARCA4-mutated cancers) is a proven clinical strategy, drawing parallels to the success of PARP inhibitors in other cancer types.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through pipeline advancement, positive clinical trial progress, and extended cash runway, though continued net losses represent ongoing dilution risk.
• Employees: Continued employment and opportunities in research and development due to ongoing program advancement and strong financial position.
• Patients: Potential for new, precision-targeted therapies for various cancers, particularly those with SMARCA4, EP300, ARID1A, and CBP mutations, addressing significant unmet medical needs.
• Partners (Lilly): Continued collaboration and potential for shared success from the SMARCA2 oncology program and other discovery programs.
• Creditors: Strong cash position and extended runway indicate good financial health for meeting short-to-medium term obligations.

Next Steps

• Continue enrollment in the Phase 1 dose escalation trial of FHD-909 in SMARCA4-mutated cancers.
• Further clinical exploration of FHD-909 in combination with KRAS inhibitors and pembrolizumab in NSCLC.
• Advance the Selective CBP degrader program through IND-enabling studies, targeting an IND in 2026.
• Provide program updates for the Selective EP300 degrader in Q4 2025.
• Provide program updates for the Selective ARID1B degrader in Q4 2025.
• Continue investments in novel ligases, long-acting injectables, oral delivery, and induced proximity within the chromatin biology and degrader platform.
• Potentially disclose and advance Lilly Target #2 towards IND/Phase 1 initiation.

Key Dates

Recommendation

While the company demonstrates strong pipeline progress, reduced net loss, and a solid cash runway, it remains a clinical-stage biotechnology company with its lead asset in Phase 1. The positive preclinical data and strategic collaborations are encouraging, but significant clinical milestones and regulatory approvals are still years away. A 'hold' recommendation allows investors to maintain their position, acknowledging the long-term potential while awaiting more mature clinical data and further de-risking of the pipeline before considering a 'buy' or 'strong buy' position. The increased stockholders deficit also warrants caution.

Keywords

Biotechnology, Oncology, Gene Traffic Control Platform, SMARCA2 inhibitor, Protein degrader, Clinical trials, Cancer therapy, Non-small cell lung cancer, Precision medicine, Drug development, Financial results